SSG
HRMY icon

Summit Securities Group’s Harmony Biosciences HRMY Stock Holding History

Summit Securities Group’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10
Closed – – 659
2024
Q1 		$0 Buy
+10
New +$321 ﹤0.01% 667

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Securities Group's HRMY Position: Q2 2024 in Review

Summit Securities Group sold out of Harmony Biosciences (HRMY) in Q2 2024, closing a stake of 10 shares.

Summit Securities Group first reported a position in HRMY in Q1 2024 and held it in 1 quarter. The position peaked at $0 in Q1 2024. 219 funds tracked by Wall St. Rank hold HRMY as of Q2 2024.

  • Summit Securities Group reported no remaining Harmony Biosciences position as of Q2 2024 after selling out during the quarter.
  • Summit Securities Group sold 10 Harmony Biosciences shares in Q2 2024.
  • Summit Securities Group first reported a position in Harmony Biosciences in Q1 2024 and held it in 1 quarter.
  • Summit Securities Group's Harmony Biosciences position peaked at $0 in Q1 2024.
  • 219 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2024.

Based on Summit Securities Group's 13F filing for Q2 2024, filed 26 Jul 2024.